Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 8/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102403 | 0.91 | TRPV4 (0.43) | P2RY14GPR139 | |
| SCHEMBL13101690 | 0.88 | ALDH1A1 (0.49) | P2RY14GPR139 | |
| SCHEMBL13102005 | 0.87 | KDM4E (0.43) | FFAR2GPR139CSNK1DRIPK1 | |
| SCHEMBL13102401 | 0.87 | GLS (0.39) | FFAR2GLS | |
| SCHEMBL13102078 | 0.86 | SLC2A1 (0.43) | P2RY14FFAR2GLSGPR139CSNK1D | |
| SCHEMBL13101980 | 0.86 | GPR139 (0.46) | P2RY14FFAR2GPR139CSNK1DCTSD | |
| SCHEMBL13102285 | 0.86 | NPSR1 (0.44) | — | |
| SCHEMBL13102493 | 0.85 | ALDH1A1 (0.40) | GPR139 | |
| SCHEMBL13102419 | 0.84 | MEN1 (0.39) | GPR139 | |
| SCHEMBL13101991 | 0.83 | RORC (0.41) | P2RY14GPR139RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | P2RY14 1272/4885FFAR2 1609/4885GLS 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.